ArticleTherapeutics and clinical risk management2026
Association Between Insulin Regimen and Cardiovascular Risk in Indonesian Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Study.
Article in Therapeutics and clinical risk management, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality among patients with type 2 diabetes mellitus (T2DM). Despite the widespread use of insulin therapy, evidence on how different insulin regimens influence cardiovascular risk stratification remains limited and inconsistent, particularly in Asian populations, including Indonesia. Purpose: To evaluate the association between insulin regimens and cardiovascular risk, as assessed by the Framingham Risk Score (FRS), among patients with T2DM. Methods: A cross-sectional study was conducted involving 118 patients with T2DM receiving insulin therapy, including basal insulin therapy and combined basal-prandial insulin therapy. Cardiovascular risk was assessed using the FRS and categorized as low, moderate, or high. Differences between groups were analyzed using the Chi-square test. The association between insulin regimen and cardiovascular risk was evaluated using ordinal logistic regression. Results: Most patients in both treatment groups were classified as having high cardiovascular risk according to the FRS. After adjustment for potential confounders, the insulin regimen was not significantly associated with cardiovascular risk (OR = 2.14; 95% CI: 0.81-5.65; p = 0.124). In contrast, the duration of T2DM was significantly associated with cardiovascular risk (OR = 3.63; 95% CI: 1.30-10.15; p = 0.014). Conclusion: Cardiovascular risk among patients with T2DM receiving insulin therapy was predominantly moderate to high. The insulin regimen was not significantly associated with cardiovascular risk, whereas the duration of T2DM played a more prominent role in cardiovascular risk stratification.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.